Connect with us


IgA Nephropathy Market Report 2023-2033: Share, Size, Growth, and Forecast



IgA Nephropathy Market

According to IMARC Group’s latest research report, titled “IgA Nephropathy (IgAN) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033,” A nephropathy (IgAN) refers to a rare autoimmune disease that affects the kidneys. It is characterized by predominant IgA protein deposition and impairment of blood filtration in the kidney’s tiny blood channels. Its symptoms include high blood pressure, little urination, edema, and fatigue. Its diagnosis involves a urine examination to check for the presence of protein or blood in the urine, a blood test to detect the levels of cholesterol, protein, and wastes in the blood, and a glomerular filtration rate (GFR) test to determine how well the kidneys filter waste from the body and kidney biopsy to check if any IgA antibody is present in the glomerulus to aid the body in fighting this sickness. It can be treated using various alternatives, such as antihypertensive drugs, immunosuppressants, and diuretics.

Global IgA Nephropathy Market Growth:

The rising prevalence of chronic glomerular diseases is driving the IgA nephropathy (IgAN) market. Moreover, the increasing health awareness and the widespread adoption of supportive measures, including lifestyle modification, including dietary sodium and protein restriction, smoking cessation, weight control, and regular exercise by the masses, is augmenting the market. Apart from this, increasing investments by the governments to advance the healthcare infrastructure is propelling the market favorably. Additionally, the growing number of government initiatives to spread awareness and the rising geriatric population are acting as other growth-inducing factors. Besides, the emergence of regenerative medicine and the growing utilization of telemedicine across the healthcare sector is fostering the market.

Get Free Sample Copy of Report at –

Key Market Segmentation:

Time Period of the Study:

  • Base Year: 2022
  • Historical Period: 2017-2022
  • Market Forecast: 2023-2033

Analysis Covered Across Each Country:

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the igA nephropathy (IgAN) market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the igA nephropathy (IgAN) market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs

In-Market Drugs:

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Regulatory Status

Countries Covered:

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Key Highlights of the Report:

  • Market Performance 
  • Market Outlook
  • Porter’s Five Forces Analysis
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Value Chain
  • Comprehensive Mapping of the Competitive Landscape